[Radioimmunologic analysis of ferritin, carcinoembryonic antigen and prolactin for evaluating the prognosis and effectiveness of treating breast cancer].
The levels of tumor markers--CEA, ferritin and prolactin (the hormone of the anterior pituitary gland) were studied in the blood serum of 178 breast cancer patients in the menopause during combined therapy using a radioimmunoassay. This combination was shown to be informative for assessment of prognosis of disease and efficacy of antitumor therapy which was confirmed by clinical and x-ray findings and observation of a tumor process in breast cancer patients over a 5-year period.
Skliar
S Iu
SIu
Chebotareva
E D
ED
Ganul
V L
VL
Korolev
V I
VI
D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood / Q000628:therapy*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D005260:Female; D005293:Ferritins / Q000097:blood*; D006801:Humans; D011379:Prognosis; D011388:Prolactin / Q000097:blood*; D011863:Radioimmunoassay
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D011388:Prolactin; D005293:Ferritins
Radioimmunologicheskiĭ analiz ferritina, rakogo-émbrional'nogo antigena i prolaktina dlia otsenki prognoza i éffektivnosti lecheniia raka molochnoĭ zhelezy.